Table 4.
Incidence Rates (IR) for Treated Hepatitis C by Exposure in Patients with Psoriasis or PsA
| Exposure at Index Date | Cases | Person-Years | IR per 1000 PY (95% CI) |
|---|---|---|---|
| All Patients | N=150 | Total=255,451 | 0.6 (0.5–0.7) |
| DMARDs only | 13 | 25,865 | 0.5 (0.3–0.9) |
| Apremilast | 12 | 17,180 | 0.7 (0.4–1.2) |
| Apremilast only | 8 | 12,842 | 0.6 (0.3–1.2) |
| Apremilast + other | 4 | 4338 | 0.9 (0.2–2.4) |
| TNF-i biologics only | 44 | 75,547 | 0.6 (0.4–0.8) |
| IL-i biologics only | 14 | 25,654 | 0.5 (0.3–0.9) |
| CS only | 17 | 13,943 | 1.2 (0.7–2.0) |
| DMARDs + CS | 0 | 5990 | 0.0 (0.0–0.6) |
| TNF-i with DMARDs and/or CS | 14 | 23,806 | 0.6 (0.3–1.0) |
| IL-i with DMARDs and/or CS | 2 | 4742 | 0.4 (0.0–1.5) |
| Unexposed | 34 | 62,723 | 0.5 (0.4–0.8) |
Note: Number of cases were too small to calculate stable IRR estimates.
Abbreviations: CI, confidence interval; CS, corticosteroids; DMARDs, disease-modifying antirheumatic drugs; IL-i, interleukin-17, −23 or −12/23 inhibitor biologics; IR, incidence rate; PY, person-years; TNF-i, tumor necrosis factor inhibitor biologics.